mTOR抑制剂耐药机制及预测依维莫司疗效标志物的研究进展  

Progress on Mechanism of Resistance to mTOR Inhibitor and Predicting Biomarkers for Everolimus Efficacy

作　　者：谭玉靓 樊英 TAN Yujing;FAN Ying(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院,北京100021

出　　处：《肿瘤学杂志》2024年第1期18-24,共7页Journal of Chinese Oncology

基　　金：中国医学科学院肿瘤医院内科重点学科发展基金(CICAMSMOMP2022003)。

摘　　要：依维莫司是一种哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂,可改善晚期激素受体阳性/人表皮生长因子受体2阴性(hormone receptor-positive/human epidermal growth factor receptor 2-negative,HR+/HER2-)乳腺癌患者的预后。然而,依维莫司耐药日益发展,缺乏有效的标志物预测其疗效,对其临床应用造成了挑战。针对这一重要的临床问题,全文整理了近年来mTOR抑制剂的耐药机制及依维莫司疗效预测标志物的相关研究,以期提供参考。Everolimus,a mammalian target of rapamycin(mTOR)inhibitor,has been shown to improve survival of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)advanced breast cancer.However,resistance to everolimus has been increasingly developed,and there is no efficient biomarker to predict its efficacy,which becomes a challenge for the clinical use of everolimus.This paper reviews the mechanisms of resistance to mTOR inhibitor and potential markers that can predict the efficacy of everolimus.

关 键 词：乳腺癌 耐药 哺乳动物雷帕霉素靶蛋白抑制剂 依维莫司 疗效标志物 

分 类 号：R737.9[医药卫生—肿瘤]